Used as a selective inhibitor of the DNA repair enzyme PARP1, AZ876 is employed in cancer research to enhance the effectiveness of DNA-damaging agents such as chemotherapy and radiation. It shows potential in studies involving synthetic lethality, particularly in tumors with BRCA1 or BRCA2 deficiencies. Its application is primarily in preclinical investigations to evaluate antitumor activity and combination therapy strategies.